Navigation Links
Laut einer Studie setzen sich die großen Pharmaunternehmen mehr für den Zugang zu Medizin in Entwicklungsländern ein als noch vor zwei Jahren
Date:11/27/2012

AMSTERDAM, November 28, 2012 /PRNewswire/ --

Der jüngste "Access to Medicine Index", der die führenden 20 Pharmaunternehmen nach ihren Bemühungen beurteilt, ihre Medikamente in Entwicklungsländern besser zugänglich zu machen, stellte fest, dass die Branche in diesem Punkt besser abschneidet als noch vor zwei Jahren. GlaxoSmithKline übertrifft dabei weiterhin die anderen Unternehmen, doch immer mehr führende Pharmaunternehmen schließen auf.

     (Photo: http://photos.prnewswire.com/prnh/20121128/579726 )

Der am Mittwoch veröffentlichte Index führt Johnson & Johnson als einen der stärksten Aufsteiger an; das Unternehmen konnte sich von der 9. Position und dem Mittelfeld im Index des Jahres 2010 in diesem Jahr auf den 2. Rang nur knapp hinter GlaxoSmithKline hocharbeiten. Das Unternehmen ist dabei einer der beiden Newcomer in den Top 3. Der Aufstieg ist im Wesentlichen der Konsolidierung seiner Aktivitäten in Hinblick auf die Verbesserung des Medikamentenzugangs unter einer einzigen Geschäftseinheit, was eine strategischere und stärker integrierte Vorgehensweise ermöglicht hat, sowie der Akquisition des Impfstoffherstellers Crucell zu verdanken, wodurch die Relevanz der Investitionen in Forschung und Entwicklung verbessert wurde. Zudem hat das Unternehmen auch insgesamt mehr über die Aktivitäten zur Verbesserung des Medikamentenzugangs bekannt gegeben.

"Der diesjährige Index zeigt, dass die Unternehmen bei ihren Bemühungen zur Verbesserung des Zugangs zu medizinischer Versorgung intern besser organisiert sind und jene, denen dies am besten gelingt, tendenziell auch in den anderen von uns erfassten Bereichen besser abschneiden. Die führenden Unternehmen legen die Latte immer höher", erklärte Wim Leereveld, Gründer und CEO des Access t
'/>"/>

SOURCE Access to Medicine Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
2. Desitin Pharmaceuticals entscheidet sich für das cloudbasierte Veeva CRM zur Unterstützung seiner Expansion auf den britischen Markt
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
11. Pulse Oximetry Screening Hailed as the New Milestone to Combat Critical Congenital Heart Disease - Signal Extraction Technology Leading the Way in Large, Independent Clinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Calif. , Aug. 3, 2015  Isis ... today announced a strategic collaboration to discover and ... diseases. The new collaboration builds on a broad ... AstraZeneca,s strategic approach in these therapeutic areas using ... to extend use of its antisense technology to ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 /PRNewswire/ ... needs of customers who are increasingly mobile, increasingly connected, ... support a growing variety of customer interaction channels and ... of technology, including social media. According ... of the over the counter (OTC) segment in a ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to ... University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative ... Africa. , A cooperative agreement awarded by the U.S. Agency for International ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato ... new program “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive ... healthcare organizations with access to the tactics, techniques and practices required to design ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... - When given alongside radiation therapy for head and ... to reduce the debilitating side effect of xerostomia, according ... Anderson Cancer Center and Fudan University Shanghai Cancer Center. ... , reported findings from the first randomized controlled trial ...
... press release is available in French . , ... metastasis has been identified by a team of researchers led by ... Health Centre (RI-MUHC). Complications in breast cancer patients are commonly caused ... of the body, most often to the bones and lungs. These ...
... Norwegians, the investigators found that alcohol consumption was associated ... from coronary artery disease. For men, the fully ... CI 0.39 - 0.69) when comparing subjects reporting more ... or rarely drinking; for women, it was 0.62 (0.3-.23). ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... , THURSDAY, Nov. 10 (HealthDay News) -- ,Heavy ... according to a new study. It also confirmed ... and schizophrenia. Methamphetamine and other amphetamine-type stimulants are ... worldwide. In this study, researchers at the Centre ...
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay ... livers are typically subject to a mandatory six-month "dry-out" ... Unfortunately, many of the sickest of these patients fail ... that earlier transplants can dramatically improve survival odds in ...
Cached Medicine News:Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 3Health News:New target identified to stop the spread of breast cancer 2Health News:Flexible rack systems sort molecules 2Health News:Heavy Meth Use Linked to Schizophrenia 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 3
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
... - 200: 200V, .01-2A. 300: 300V, 4-400mA. ... Select constant voltage or constant current ... gels. - Compact, lightweight and stackable. - ... - Ideal for DNA, RNA and protein ...
... The MAX POWER Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
Medicine Products: